700 patients110,866 observations180 daysLIVE

Patient P-02398

Synthetic patientMETA-24 · Day 175 · 35–44 · F · baseline S06Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
43%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S06
  2. Day 115 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 122 GI-04 recommendedGI Support Protocol GI-04
  4. Day 123 Patient acceptedStarted GI-04 in the companion
  5. Day 131 GI symptom burden −23% vs expectedGI Support Protocol GI-04
  6. Day 137 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 115.

Primary contributors, last 14 days
  • Toxicity-12
  • Inflammatory activity-10
  • Nutritional resilience+6
  • GI instability-5
  • Treatment adherence-4

What helped?

  • GI Support Protocol GI-04Day 122
    Result: symptom burden −23%
LIFE OS recommendation
Dietary Support Protocol NP-02
47%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 69% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
21 min
improving · +3.2 vs previous 14 d
Sleep duration
Wearable
4.9 h
stable · +0.0 vs previous 14 d
Energy level
Daily log
4/10
improving · +0.4 vs previous 14 d
Steps
Wearable
2,206
improving · +140 vs previous 14 d
GI burden
Companion
45.9/100
improving · -5.9 vs previous 14 d
Adherence
Companion
71 %
stable · -1.4 vs previous 14 d
Sleep quality
Wearable
24.6/100
stable · +0.6 vs previous 14 d
Glucose, CGM daily mean
CGM
146 mg/dL
stable · -2.2 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →

Heading towards restoration · 49 from the failing basin, 41 from restoration.

Good elements to keep
  • GI Support Protocol GI-04
    intervention · steering +36
  • Protein (supports)
    perturbation · steering +13
  • Daily walks resumed
    perturbation · steering +3.3
  • Protein
    supporter · GI -7 next day
Main detractors to watch
  • Low butyrate capacity
    hidden · steering -17.5
  • Ultra-processed food
    perturbation · steering -12.1
  • Dietary fat load
    perturbation · steering -11.6
  • FUT2 non-secretor
    hidden · steering -10.6
  • Ultra-processed food
    detractor · GI +7.2 next day
  • Dietary fat load
    detractor · GI +6.9 next day
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Ultra-processed food
    +7.2detractor · 95%
  • Protein
    -7supporter · 95%
  • Dietary fat load
    +6.9detractor · 95%
  • Histamine load
    +5.5detractor · 95%
  • Simple carbohydrates
    +5.3detractor · 95%
  • Alcohol
    -2.4no signal · 48%
  • Caffeine
    +1no signal · 18%
  • Insoluble fibre
    +0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 48
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 46 and rising
    • WearableSleep 4.9 h, below personal baseline
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 25/100
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 40
    • Wearable2,206 steps/day
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 25/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
48 ms
Sleep
5.2 h
Steps
1,078
Resting HR
70 bpm
Daily log: GI score 46, nutritional resilience 50, adherence 71.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0217024%S0480
P-0204827%S0277
P-0211527%S14GI-04improved75
P-0238825%S1175
P-0257525%S14ME-01improved73
P-0255324%S1371
P-0240324%S0371
P-0233526%S0470
P-0255026%S0170
P-0206224%S2070
P-0219225%S0569
P-0265931%S0969